Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company

Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region

Fineline Cube Oct 23, 2023

Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which...

Company Drug

Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization

Fineline Cube Oct 23, 2023

Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal...

Policy / Regulatory

National VBP Tender Program Invites Drugs Approved Before October 30 for Round 9

Fineline Cube Oct 23, 2023

The National Allied Procurement Office has released a notification regarding Round 9 of the national...

Company Deals

MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech

Fineline Cube Oct 23, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan...

Company Drug

Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management

Fineline Cube Oct 23, 2023

Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...

Company

Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing

Fineline Cube Oct 23, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...

Company Drug

Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors

Fineline Cube Oct 23, 2023

China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...

Company Deals

AcuVu Medical Partners with Hologic for US Distribution of HummingScope Hysteroscopy System

Fineline Cube Oct 23, 2023

AcuVu Medical, a specialist in electronic endoscopes with operations in California, USA, and Suzhou, China,...

Company Deals

CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA

Fineline Cube Oct 23, 2023

CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in...

Company Drug

BeiGene’s Brukinsa Gains NICE Recommendation for CLL Treatment in the UK

Fineline Cube Oct 23, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National...

Company Drug

Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation

Fineline Cube Oct 23, 2023

China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...

Company Deals

Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development

Fineline Cube Oct 23, 2023

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging...

Company Deals

Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089

Fineline Cube Oct 23, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...

Company Drug

InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023

Fineline Cube Oct 23, 2023

China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...

Company Deals

Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China

Fineline Cube Oct 23, 2023

US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing...

Company Medical Device

Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific

Fineline Cube Oct 20, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...

Company Deals

Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million

Fineline Cube Oct 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9...

Company Drug

Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C

Fineline Cube Oct 20, 2023

China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...

Company Drug

Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment

Fineline Cube Oct 20, 2023

Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical...

Company Drug

Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR

Fineline Cube Oct 20, 2023

China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of...

Posts pagination

1 … 457 458 459 … 667

Recent updates

  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.